All In Biotech

Drug Trial Radar · NCT06794268

A Study to Patients With Relapsed/Refractory Follicular Lymphoma Treated With Liso-cel (Lisocabtagene Maraleucel) in the Post Marketing Setting

Non-interventional Cohort Study of Patients Treated With Liso-cel (Lisocabtagene Maraleucel) for Relapsed/Refractory Follicular Lymphoma in the Postmarketing Setting

Last checked: Nov 19, 2026Latest source record: Feb 24, 2025 (this record)Source: ClinicalTrials.govMethods & limitations

Recruiting

Status

Recruiting

Enrollment

300

Planned (sponsor's estimate)

Start

Feb 4, 2025

Primary completion

Aug 31, 2044

Study completion Aug 31, 2044

Sponsor

Lead sponsor
Juno Therapeutics, Inc., a Bristol-Myers Squibb CompanyBristol Myers Squibb (BMY)
Sponsor type
Industry
First posted
Jan 27, 2025

More drug trials from this sponsor

Design

Study type
Observational
FDA-regulated drug
Yes
Who can join
All sexes, from 18 years
Healthy volunteers
No

Summary

As written by the sponsor on the registry.

The purpose of this study is to characterise the long-term safety of lisocabtagene maraleucel, focusing on patients treated in the approved follicular lymphoma (FL) indication, and will be part of post-marketing liso-cel pharmacovigilance activities

Conditions

  • Follicular Lymphoma

Interventions

  • Lisocabtagene maraleucelBiological

    As per product label

Primary outcomes

What the sponsor says the trial is designed to measure.

  1. Incidence of adverse events (AEs) of interestTime frame: Up to 15 years
  2. Incidence of other adverse events (AEs) of interestTime frame: Up to 15 years

Locations

1 site in 1 country. Site status is shown where the registry gives one.

  • CIBMTR

    Milwaukee, Wisconsin · Recruiting

Contact details for sites and study staff are not shown here. To ask about taking part, use the contact information on the registry record.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.